Umeclidinium Bromide

乌美溴铵

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameUmeclidinium Bromide
Drug Alias Name芜地溴铵Ellipta IncruseUmeclidinii bromidum乌美利溴铵Encruse Ellipta +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMuscarinic acetylcholine receptor M1 antagonistsMuscarinic acetylcholine receptor M5 antagonistsMuscarinic acetylcholine receptor M3 antagonists +[5] 
TargetsMuscarinic acetylcholine receptor M2Muscarinic acetylcholine receptor M1Muscarinic acetylcholine receptor M5 +[5] 
Therapy Area/IndicationsHyperhidrosisPulmonary Disease, Chronic ObstructiveAsthma
Global Approved IndicationsPulmonary Disease, Chronic Obstructive
Approved Indications in ChinaPulmonary Disease, Chronic Obstructive
Original Approved Country/TerritoryCanada
Original Approved Date2014/04/17
Country/TerritoryCzechiaBelgiumBulgaria +[34] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcGlaxosmithkline (Ireland) LtdGlaxo Group Limited, England +[4] 
Inactive CompaniesStiefel LaboratoriesQueen'S UniversityGlaxo Operations Uk Ltd +[4] 
Active IndicationsPulmonary Disease, Chronic Obstructive
Inactive IndicationsHyperhidrosisAsthma

Other Information

ATC CodeR03BB07
Related LinksWikipediaDrugBankKEGG